THERAPY DOSSIER · th-16c35a58e470

Maltol

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL31422 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: 2-methylpyromeconic acid; Larixic acid; Palatone; Veltol; E-636; NSC-2829
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07308769 ↗PHASE4recruiting

Efficacy and Tolerability of Sucrosomial Iron vs Ferric Maltol in Iron Deficient Women

Anemia · Iron Deficiency Anemia (IDA)

Enrolment: 146 · Results not recorded

NCT02968368 ↗PHASE3completed

Phase 3 Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Renal Insufficiency, Chronic · Iron-Deficiency Anemia

Enrolment: 167 · Results not recorded

NCT05126901 ↗PHASE3completed

Safety and Efficacy of Ferric Maltol (ST10) Oral Suspension Compared to Ferrous Sulfate Oral Liquid in Children and Adolescents With Iron-deficiency Anaemia

Anemia · Iron-deficiency

Enrolment: 65 · Results not recorded

NCT03371173 ↗PHASE3terminated

Pilot Study of Oral Iron Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension and Iron Deficiency Anemia

Hypertension, Pulmonary · Anemia, Iron Deficiency

Enrolment: 22 · Results not recorded

NCT01340872 ↗PHASE3completed

Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis (AEGIS 1)

Iron Deficiency Anaemia · Inflammatory Bowel Disease · Ulcerative Colitis

Enrolment: 128 · Results not recorded

NCT05177484 ↗PHASE3completed

Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery

Cancer Colon

Enrolment: 40 · Results not recorded

NCT04626414 ↗PHASE1completed

Phase I Study to Compare the Pharmacokinetics of Ferric Maltol Capsules and Oral Suspension in Adult Healthy Volunteers

Anemia, Iron Deficiency

Enrolment: 32 · Results not recorded

NCT03181451 ↗PHASE1completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects Aged 10-17 With Iron Deficiency

Iron Deficiency, Anaemia in Children · Iron-Deficiency

Enrolment: 37 · Results not recorded

NCT05985070 ↗NAunknown

Evaluating the Effectiveness of Various Iron Salts in Oral Iron Therapy for Iron Deficiency and Anemia in Healthy Adults

Iron Deficiency · Iron Deficiency Anemia

Enrolment: 59 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30142916 ↗2018Reported benefit

The Liver Protection Effects of Maltol, a Flavoring Agent, on Carbon Tetrachloride-Induced Acute Liver Injury in Mice via Inhibiting Apoptosis and Inflammatory Response.

MouseChemical/toxinICRMaleIntragastric100 mg/kgPretreatment, for 15 days before carbon tetrachloride exposure; carbon tetrachl…

Model: Carbon tetrachloride-induced acute liver injury (single intraperitoneal injection of CCl4 0.25% in olive oil, 10 mL/kg body weight)

Maltol pretreatment lowered serum ALT and AST, reduced inflammatory mediator expression, suppressed hepatocyte apoptosis, attenuated the loss of catalase, glutathione and superoxide dismutase, reduced CYP2E1 and HO-1 over-expression, and improved liver histopathology after carbon tetrachloride expo…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…